217 related articles for article (PubMed ID: 35996151)
1. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.
Wu CF; Lin L; Mao YP; Deng B; Lv JW; Zheng WH; Wen DW; Kou J; Chen FP; Yang XL; Xu SS; Ma J; Zhou GQ; Sun Y
BMC Med; 2021 Aug; 19(1):193. PubMed ID: 34433440
[TBL] [Abstract][Full Text] [Related]
3. Circulating Epstein-Barr virus DNA level post induction chemotherapy contributes to prognostication in advanced-stage nasopharyngeal carcinoma.
Chen FP; Luo YS; Chen K; Li JY; Huo LQ; Shi L; Ou-Yang Y; Cao XP
Eur J Cancer; 2021 Jul; 151():63-71. PubMed ID: 33964573
[TBL] [Abstract][Full Text] [Related]
4. Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma.
Chen FP; Huang XD; Lv JW; Wen DW; Zhou GQ; Lin L; Kou J; Wu CF; Chen Y; Zheng ZQ; Li ZX; He XJ; Sun Y
Cancer; 2020 May; 126(10):2163-2173. PubMed ID: 32125701
[TBL] [Abstract][Full Text] [Related]
5. The value of integrating tumor volume and plasma Epstein-Barr virus DNA load during sequential chemoradiotherapy for prognostic prediction and therapeutic guidance in high-risk locoregionally advanced nasopharyngeal carcinoma.
Wang G; Dong Z; Huang C; Du X; Chen L; Li K; Guo R; Tang L; Ma J
Oral Oncol; 2023 Oct; 145():106500. PubMed ID: 37467683
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a joint model for dynamic prediction of overall survival in nasopharyngeal carcinoma based on longitudinal post-treatment plasma cell-free Epstein-Barr virus DNA load.
Zhu GL; Fang XL; Yang KB; Tang LL; Ma J
Oral Oncol; 2022 Nov; 134():106140. PubMed ID: 36183501
[TBL] [Abstract][Full Text] [Related]
7. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker.
Lam WKJ; Chan KCA; Lo YMD
J Pathol; 2019 Apr; 247(5):641-649. PubMed ID: 30714167
[TBL] [Abstract][Full Text] [Related]
8. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract][Full Text] [Related]
9. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Khakoo S; Carter PD; Brown G; Valeri N; Picchia S; Bali MA; Shaikh R; Jones T; Begum R; Rana I; Wotherspoon A; Terlizzo M; von Loga K; Kalaitzaki E; Saffery C; Watkins D; Tait D; Chau I; Starling N; Hubank M; Cunningham D
Clin Cancer Res; 2020 Jan; 26(1):183-192. PubMed ID: 31852830
[TBL] [Abstract][Full Text] [Related]
10. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
[TBL] [Abstract][Full Text] [Related]
11. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
[TBL] [Abstract][Full Text] [Related]
13. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
[TBL] [Abstract][Full Text] [Related]
14. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
[TBL] [Abstract][Full Text] [Related]
15. Use of circulating tumour DNA in nasopharyngeal carcinoma to detect minimal residual disease.
Ghimire B; Herrman E; Karki U; Chisti MM
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35750431
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
18. The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era?: a systematic review and meta-analysis of 7836 cases.
Zhang W; Chen Y; Chen L; Guo R; Zhou G; Tang L; Mao Y; Li W; Liu X; Du X; Sun Y; Ma J
Medicine (Baltimore); 2015 May; 94(20):e845. PubMed ID: 25997061
[TBL] [Abstract][Full Text] [Related]
19. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
20. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]